Showing 1 - 10 of 158
Persistent link: https://www.econbiz.de/10011589279
Persistent link: https://www.econbiz.de/10010515278
Persistent link: https://www.econbiz.de/10003379831
Persistent link: https://www.econbiz.de/10003278390
We consider a therapeutic market with potentially three pharmaceutical firms. Two of the firms offer horizontally differentiated brand-name drugs. One of the brand-name drugs is a new treatment under patent protection that will be introduced if the profits are sufficient to cover the entry...
Persistent link: https://www.econbiz.de/10003393611
Persistent link: https://www.econbiz.de/10003459149
Persistent link: https://www.econbiz.de/10003241696
In this paper we study the effect of reference pricing on pharmaceutical prices and expenditures when generic entry is endogenously determined. We develop a Salop-type model where a brand-name producer competes with generic producers in terms of prices. In the market there are two types of...
Persistent link: https://www.econbiz.de/10013024341
Therapeutic reference pricing (TRP) of pharmaceuticals is widely thought to steer drug innovation incentives away from …
Persistent link: https://www.econbiz.de/10014243453
Persistent link: https://www.econbiz.de/10013350399